A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
Latest Information Update: 16 Nov 2017
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Panobinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
- 26 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.